Media Center

In the media

AbilityPharma rises 1.2M euros with the biggest round of Capitall Cell

December 7, 2018

10/12/2018

AbilityPharma recibe su tercera designación de medicamento huérfano por la FDA

Expansión

08/11/2018

TechShare, el programa que abre las puertas de la Bolsa a las pymes biotech

Innovaspain

26/09/2018

Cómo facilitar la salida a bolsa de empresas biotecnológicas

Diario Medico

26/09/2018

ABILITY PHARMA COMENÇA LA FASE 2 DEL SEU NOU ANTICANCERIGEN

La Vanguardia

20/09/2018

ABILITYPHARMA ABRE UNA RONDA PARA LUCHAR CONTRA EL CÁNCER

Expansión

13/09/2018

The FDA approves a clinical trial of AbilityPharma

Expansión

20/02/2018

Ability Pharma gets FDA nod for a new clinical trials

Diari de Sabadell

20/02/2018

Ability receives FDA authorization to start clinical trials

Expansión

14/12/2017

Ability Pharma seeks 2.5 million to expand clinical trials

Expansión

09/10/2017

Ability Pharma receives the OK from France for testing a new drug

Diari Sabadell

09/10/2017

ABILITY PHARMA ACHIEVES THE DISTINCTION OF ORPHAN DRUG IN THE EU

Expansión

19/09/2017

REWARD TO MINORYX AND ABILITY AUDACITY

Expansión

15/12/2016

Ability Pharma strengthens in the US

El Periódico

14/12/2016

AbilityPharma starts the Phase 2 with the anticancer drug ABTL0812

Diari de Sabadell

06/12/2016

The phase 2 of the antitumoral drug starts

La Vanguardia

23/11/2016

Start of a clinical trial with a new drug for lung and endometiral cancer

La Vanguardia online

22/11/2016

ABTL0812, from AbilityPharmaceuticals, is designed Orphan

Diaro Médico

08/04/2015

European support to the oncology investigation

La Vanguardia

08/04/2015

Ability Pharmaceuticals Receives Positive Opinion from EMA for Orphan Drug Status of ABTL0812 in Pediatric Cancer Neuroblastoma

Siege to cancer from Bellaterra

L'Econòmic - El Punt Avui

19/02/2013

The biomedical company Ability Pharmaceuticals obtains financing for a pioneering treatment for pancreatic and lung cancer in humans

LATEST NEWS

05.12.2018

News

AbilityPharma ha superado el millón de euros en la ronda de crowdfunding que abrió el pasado mes de septiembre + info
07.11.2018

News

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Biliary Tract Cancer + info
19.09.2018

News

Ability Pharmaceuticals anuncia la inclusión del primer paciente en el estudio clínico de la fase 2 de ABTL0812 en Francia + info
24.08.2018

News

At AbilityPharma we are very pleased to announce the start of a crowdfunding campaign through de Capital Cell + info
19.02.2018

News

AbilityPharma Announces FDA Approval of Phase 1/2 Trial of ABTL0812 for Patients with Advanced Metastatic Pancreatic Cancer + info
13.12.2017

News

AbilityPharma Announces FDA Approval of IND for Phase 2 Trial of ABTL0812 in Patients with Endometrial Cancer or Squamous Non-Small Cell Lung Cancer + info
05.10.2017

News

Ability Pharmaceuticals announces the approval from the French Medicines Agency ANSM to initiate a Phase 1/2a Clinical Trial with ABTL0812 to treat patients with endometrial cancer or squamous lung cancer as first-line therapy in France + info
18.09.2017

News

Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
07.03.2017

News

Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG